



Sobczyk-Barad, M. K., & Gaunt, T. R. (2022). Reply to Janssen et al. Comment on “Sobczyk, M.K.; Gaunt, T.R. The Effect of Circulating Zinc, Selenium, Copper and Vitamin K1 on COVID-19 Outcomes: A Mendelian Randomization Study. *Nutrients* 2022, 14, 233. *Nutrients*, 14(5), 1-2. [1113]. <https://doi.org/10.3390/nu14051113>

Publisher's PDF, also known as Version of record

License (if available):  
CC BY

Link to published version (if available):  
[10.3390/nu14051113](https://doi.org/10.3390/nu14051113)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

This is the final published version of the article (version of record). It first appeared online via MDPI at <https://doi.org/10.3390/nu14051113> . Please refer to any applicable terms of use of the publisher.

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: <http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

Reply

# Reply to Janssen et al. Comment on “Sobczyk, M.K.; Gaunt, T.R. The Effect of Circulating Zinc, Selenium, Copper and Vitamin K<sub>1</sub> on COVID-19 Outcomes: A Mendelian Randomization Study. *Nutrients* 2022, 14, 233”

Maria K. Sobczyk \* and Tom R. Gaunt

MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol BS8 2BN, UK; tom.gaunt@bristol.ac.uk

\* Correspondence: maria.sobczyk@bristol.ac.uk



**Citation:** Sobczyk, M.K.; Gaunt, T.R. Reply to Janssen et al. Comment on “Sobczyk, M.K.; Gaunt, T.R. The Effect of Circulating Zinc, Selenium, Copper and Vitamin K<sub>1</sub> on COVID-19 Outcomes: A Mendelian Randomization Study. *Nutrients* 2022, 14, 233”. *Nutrients* 2022, 14, 1113. <https://doi.org/10.3390/nu14051113>

Academic Editor: Susanna C. Larsson

Received: 25 January 2022

Accepted: 28 January 2022

Published: 7 March 2022

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

In their correspondence arising from our recent manuscript [1], Janssen et al. [2] largely repeat the limitations we presented in the Discussion of our Mendelian randomization (MR) analysis that aimed to establish causal relationships between vitamin K<sub>1</sub> levels and COVID-19 outcomes: infection, hospitalization, and a very severe disease course. In our manuscript we acknowledged that the MR analysis suffers from relatively low power influenced both by the power of exposure in the outcome GWAS, and “winners’ curse” in the exposure GWAS. We concluded that we find limited statistical evidence for vitamin K<sub>1</sub>’s role in COVID-19 (but do not claim that this lack of evidence is evidence of no effect): the point estimates in the main method (IVW) point to slightly reduced very severe COVID and hospitalizations (versus the general population) being associated with higher genetically predicted circulating vitamin K<sub>1</sub> levels.

However, previous MR investigations using the same circulating phyloquinone GWAS for genetic instrument selection and effect-size estimates did uncover strong evidence for a modest causal effect on type 2 diabetes [3] and large artery atherosclerotic stroke [4]. This is why our manuscript encourages future investigations using better-powered exposure and outcome GWAS.

Furthermore, in our manuscript we concluded that effect estimates obtained in our MR analysis relate to the preventative effect of the naturally occurring range of circulating phyloquinone concentration prior to infection; moreover, we confirm that our analysis was not intended to mirror the potential therapeutic effect of high-dose clinical interventions which may be needed for seriously ill, hospitalized individuals.

Contrary to the implicit suggestion in Janssen et al. [2], there is no gold-standard biomarker for determining extrahepatic vitamin K status, with blood phyloquinone (genetically instrumented in our study), PIVKA-II and dp-ucMGP (used by Janssen and colleagues in their research) widely used and attributed to a specific set of strengths and disadvantages; this is reviewed in-depth elsewhere [5,6]. We acknowledge that genetic instruments for dp-ucMGP are available [7] and that additional MR analyses involving them could complement our study.

In their closing paragraph, Janssen et al. [2] state that: “we are of the opinion that their (i.e., Sobczyk & Gaunt 2022) genetic data analysis is interesting but cannot be used to decide whether vitamin K supplementation has a role in COVID-19”; this agrees with the sentiment expressed in our manuscript, as shown by the multiple limitations we described and our concluding statement about the lack of evidence from our analysis.

The previous track record of vitamins (such as D) and micronutrients (such as zinc) with plausible mechanistic pathways and much more accumulated observational evidence than vitamin K in randomized controlled trials (RCT) has not been encouraging [8]. This is why we await with interest the publication of results from the phase 2 trial on vitamin K<sub>2</sub>

supplementation in COVID-19, which is led by Janssen’s co-authors and industry collaborators (KOVIT trial, ClinicalTrials.gov Identifier: NCT04770740, estimated completion date October 2021), and includes pulmonary damage and coagulopathy as secondary outcomes. As with other medical interventions, vitamin supplementation can lead to side effects, and therefore, multiple strands of evidence (in vitro, animal models, RCTs etc.) may be needed to establish whether vitamin K has a role in prophylaxis and/or the therapy of COVID-19 before any clinical recommendations can be made; we certainly made no such recommendations in our own manuscript.

**Author Contributions:** Writing—original draft preparation, M.K.S.; writing—review and editing, T.R.G.; supervision, T.R.G.; funding acquisition, T.R.G. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the UK Medical Research Council [mc\_uu\_00011/4] and carried out in the MRC Integrative Epidemiology Unit.

**Conflicts of Interest:** TRG receives funding from Biogen for unrelated research.

## References

1. Sobczyk, M.K.; Gaunt, T.R. The Effect of Circulating Zinc, Selenium, Copper and Vitamin K<sub>1</sub> on COVID-19 Outcomes: A Mendelian Randomization Study. *Nutrients* **2022**, *14*, 233. [[CrossRef](#)] [[PubMed](#)]
2. Janssen, R.; Vermeer, C.; Walk, J.; Linneberg, A. Comment on Sobczyk, M.K.; Gaunt, T.R. The Effect of Circulating Zinc, Selenium, Copper and Vitamin K<sub>1</sub> on COVID-19 Outcomes: A Mendelian Randomization Study. *Nutrients* **2022**, *14*, 1112. [[CrossRef](#)]
3. Zwakenberg, S.R.; Remmelzwaal, S.; Beulens, J.W.J.; Booth, S.L.; Burgess, S.; Dashti, H.S.; Imamura, F.; Feskens, E.J.M.; van der Schouw, Y.T.; Sluijs, I. Circulating Phylloquinone Concentrations and Risk of Type 2 Diabetes: A Mendelian Randomization Study. *Diabetes* **2018**, *68*, 220–225. [[CrossRef](#)] [[PubMed](#)]
4. Larsson, S.C.; Traylor, M.; Markus, H.S. Circulating Vitamin K<sub>1</sub> Levels in Relation to Ischemic Stroke and Its Subtypes: A Mendelian Randomization Study. *Nutrients* **2018**, *10*, 1575. [[CrossRef](#)] [[PubMed](#)]
5. Shea, M.K.; Booth, S.L. Concepts and Controversies in Evaluating Vitamin K Status in Population-Based Studies. *Nutrients* **2016**, *8*, 8. [[CrossRef](#)] [[PubMed](#)]
6. Fusaro, M.; Gallieni, M.; Rizzo, M.A.; Stucchi, A.; Delanaye, P.; Cavalier, E.; Moysés, R.M.A.; Jorgetti, V.; Iervasi, G.; Giannini, S.; et al. Vitamin K plasma levels determination in human health. *Clin. Chem. Lab. Med.* **2017**, *55*, 789–799. [[CrossRef](#)] [[PubMed](#)]
7. Liu, Y.-P.; Gu, Y.-M.; Thijs, L.; Knapen, M.H.J.; Salvi, E.; Citterio, L.; Petit, T.; Carpini, S.D.; Zhang, Z.; Jacobs, L.; et al. Inactive Matrix Gla Protein Is Causally Related to Adverse Health Outcomes. *Hypertension* **2015**, *65*, 463–470. [[CrossRef](#)] [[PubMed](#)]
8. Michos, E.D.; Cainzos-Achirica, M. Supplements for the Treatment of Mild COVID-19—Challenging Health Beliefs With Science From A to Z. *JAMA Netw. Open* **2021**, *4*, e210431. [[CrossRef](#)] [[PubMed](#)]